Low-grade inflammation in the gut and increased intestinal permeability have been associated with dysfunction of the AhR/IL-22 pathway, which may lead to increased intestinal sensitization and worsening of symptoms in patients with IBS. This evidence concerns the gene IL22 and irritable bowel syndrome.